O slideshow foi denunciado.
Seu SlideShare está sendo baixado. ×

Prospective of Vatsanabha (Aconitum ferox Wall. Ex. ser ) in Cancer treatment - a review study.

Mais Conteúdo rRelacionado

Livros relacionados

Gratuito durante 30 dias do Scribd

Ver tudo

Audiolivros relacionados

Gratuito durante 30 dias do Scribd

Ver tudo

Prospective of Vatsanabha (Aconitum ferox Wall. Ex. ser ) in Cancer treatment - a review study.

  1. 1. Prospective of Vatsanabha (Aconitum ferox Wall. Ex. ser ) in Cancer treatment - a review study. Prerok Regmi1, Ravikrishna S.2, Chaithra H.3 1PG Scholar, Agadatantra Department, SDM college of Ayurveda, Udupi, Karnataka, India 2Associate Professor, Agadatantra Department, SDM college of Ayurveda, Udupi, Karnataka, India 3Professor and HOD, Agadatantra Department, SDM college of Ayurveda, Udupi, Karnataka, India Conclave on Cancer Care & Research in AYUSH: Developing a Roadmap Abstract No: 46
  2. 2. Introduction • Vatsanabha (Aconitum ferox Wall.ex. Ser) is a Mahavisha (most toxic). • Varieties of Ayurvedic formulations after the procedure of Shodhana (purification technique). • Presence of highly poisonous alkaloids. • Indian variety have a great demand in the world markets. Conclave on Cancer Care & Research in AYUSH: Developing a Roadmap
  3. 3. Purpose • Investigate the toxic components diterpenoid alkaloids. • Existing evidence of the application of A. ferox. Conclave on Cancer Care & Research in AYUSH: Developing a Roadmap
  4. 4. Methods 1. Ayurveda literature and ethnobotanical study were analysed. 2. Literature were extracted from the Pubmed indexed journals indexing “Cancer AND Aconitum. 3. Major ingredients extracted from A. ferox species were individually evaluated. Conclave on Cancer Care & Research in AYUSH: Developing a Roadmap
  5. 5. Results • Herbal drug practioners at Higher Himalayas used as a universal antidote. The root is used to treat malignant tumors. • Closely related species to ferox from extreme Himalayan mountain ecology has bore relevance to modern disease pathologies including inflammation, tumor and infections. • Diterpeniod alkaloids tend to exhibit improved after simple structural modification. • Conversion of alkaloid Aconitine (LD50 - 0.08 mg/kg) to Benzoylaconine (LD50 - 24 mg/kg) improving its safety. Conclave on Cancer Care & Research in AYUSH: Developing a Roadmap
  6. 6. Literature extracted from the Pubmed indexed journals shows few researches has been done with respect to A ferox. Invitro and invivo study of other species of Aconitum is extensively done. A. ferox species is 1.5 times as active as Aconitum chasmanthum and seven times then Aconitum nepellus Pseudaconitine, Aconitine, hypaconitine, mesaconitine, bikhaconitine, chasmaconitine, indaconitine etc. diterpenoid alkaloids are major constituents of A. ferox. These chemical constituents responses are emerging as frontline treatment agents for cancer. Conclave on Cancer Care & Research in AYUSH: Developing a Roadmap
  7. 7. Genomics support The in-vitro growth inhibitory activities MCF- 7 HCT-116 HepG2 Inactivation of the NF-κB signaling pathway. Protective autophagy through p53 activation, ERK1/2 and p38 MAPK signaling cascade. Synergistic combinations of drugs in formulation. Conclave on Cancer Care & Research in AYUSH: Developing a Roadmap
  8. 8. Phytochemical • C18 diterpeniod alkaloids: – Lappaconitine inhibiting voltage dependent sodium channels. • C19 diterpeniod alkaloids: – Aconitine – Aconitane – Pseudaconitine – Hypaconitine – Mesaconitine • C20 diterpeniod alkaloids: - Cammaconitine - Pseudokobusine • Bis-diterpenoid alkaloids: - Benzylaconine esters Conclave on Cancer Care & Research in AYUSH: Developing a Roadmap
  9. 9. Compounds Cancer types Cell lines Lycaconitine Fibroblast carcinoma KB V20C Aconitine Oral squamous cell carcinoma KBv200 Oral squamous cell carcinoma KBv200 Hepatoma carcinoma Hepal-6 Hepatoma carcinoma HePG2 Colon cancer HCT8 Breast cancer MCF7 Pseudaconitine Colon cancer MHC-I gene and protein expression Aconitane Leukemia HL-60 Deoxyaconitine Hepatoma carcinoma HePG2 Colon cancer HCT8 Breast cancer MCF7 Hepatoma carcinoma HePG2 Hypaaconitine Colon cancer HCT8 Breast cancer MCF7 Hepatoma carcinoma HePG2 Mesaconitine Colon cancer HCT8 Breast cancer MCF7 Hepatoma carcinoma HePG2 Benzoylaconine Colon Cancer HCT-15 Lung cancer A549 Breast cancer MCF-7 Conclave on Cancer Care & Research in AYUSH: Developing a Roadmap
  10. 10. Conclusion • Treatment on different Vyadhi (disease) with the context of Mahavisa . • Potentiality of most toxic alkaloids on the cancerous cell inhibition. • Emerging technique of network pharmacology can serve as a valuable tool. Conclave on Cancer Care & Research in AYUSH: Developing a Roadmap
  11. 11. Acknowledgements • Department of Agadatantra, SDM college of Ayurveda, UDUPI. Source of funding: None Conflict of interest: None Conclave on Cancer Care & Research in AYUSH: Developing a Roadmap

Notas do Editor

  •  A font size of 85pt for the title, 36–44 for the headers, and 24–34 for the body text is recommended
  • Summarize the methods used in two or three slides.
    The study design, protocol, inclusion and exclusion criteria, end points, evaluation measures etc should be described
    In case of literary research, methods used for search, interpretation, analysis etc should be described.
  • Summarize the results of the study in two or three slides. Please be brief and highlight the essential findings. Include the main statistical conclusions and its significance.
    If it is a literary study, give a summary of the interpretations and understanding arrived at.
  • The diterpinoid alkaloid vakognavia (Hanuman) amd norditerpinoid alkaloids chasmaconitine, crassicaulie, falconericine, bikhaaconine, pseudaaconie, neolie, columniaie were isolated.
  • Summarize the conclusions of your study in a few bulleted sentences.
  • Mention the acknowledgements here.
    Mention sources of funding.
    Mention any conflict of interest.

×